Pixatimod (** Pixatimod (generic name); currently investigational with no established commercial brand names. **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Pixatimod is under investigation for its potential in colorectal cancer, particularly as a modulator of the immune system to enhance antitumor activity; however, it has not yet been approved or established in clinical practice for this indication and lacks specific efficacy data in colorectal cancer patients.

Mechanism of Action

Pixatimod is an experimental drug that modulates the immune response by inhibiting phosphodiesterase-4 (PDE4), which leads to increased levels of cyclic adenosine monophosphate (cAMP) and subsequent activation of T-cells; it also exhibits anti-inflammatory properties through suppression of pro-inflammatory cytokines.

Side Effects

Fatigue; nausea; diarrhea; rash; neutropenia;

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05061017 Phase 2
Archived
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
United States

Quick Info

Brand Name** Pixatimod (generic name); currently investigational with no established commercial brand names. **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.